ESMO 2022 Conference Coverage


 

ESMO 2022 on the Phase 1 Study of PRL-02, a Long-Acting IM Depot Injection of Abiraterone Decanoate in Patients With Prostate Cancer

43 views
September 27, 2022
Comments 0
Login to view comments. Click here to Login